Last reviewed · How we verify

Myelofibrosis — Treatment Landscape & Competitive Intelligence

Myelofibrosis (Haematology) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Haematology 4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Myelofibrosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Vonjo PACRITINIB Sobi Kinase Inhibitor [EPC] Tyrosine-protein kinase JAK2 2022-01-01
Inrebic FEDRATINIB HYDROCHLORIDE Bristol-Myers Squibb JAK2, FLT3 2019-01-01
Inrebic FEDRATINIB Bristol-Myers Squibb Cyclin-G-associated kinase 2019-01-01
Jakafi RUXOLITINIB Incyte Corp Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV 2011-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bristol-Myers Squibb · 2 drugs in Myelofibrosis
  2. Incyte Corp · 1 drug in Myelofibrosis
  3. Sobi · 1 drug in Myelofibrosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Myelofibrosis:

Cite this brief

Drug Landscape (2026). Myelofibrosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/myelofibrosis. Accessed 2026-05-14.

Related